In Nature this week, a team led by researchers at St. Jude Children's Research Hospital report a novel therapy for retinoblastoma. The team performed genomic and epigenetic analyses of retinoblastoma samples, and found that the cancer's genome is stable, though several of its pathways can be deregulated. As the team reports, the only known cancer gene mutated in these tumors is RB1, and that the overall mutational rate is very low.